Industry Supported Education

An Overview of ERLEADA® (apalutamide) Efficacy, Safety and Patient-Reported Outcomes Based on the TITAN and SPARTAN Trials

For patients diagnosed with either metastatic castration-sensitive prostate cancer (mCSPC) or non-metastatic castration-resistant prostate cancer (nmCRPC), androgen deprivation therapy (ADT) has been considered the standard of care.1,2 Data from the pivotal TITAN and SPARTAN trials have shown that adding ERLEADA® (apalutamide) to ADT results in significantly increased overall survival compared with placebo plus ADT, with…